Wedbush downgrades Foghorn Therapeutics to Neutral, sets price target to $2
Wedbush downgraded Foghorn Therapeutics's stock to Neutral with a price target of $2.00, implying a downside of 31.5% from the Oct 1 close of $2.92.
Wedbush downgraded Foghorn Therapeutics's stock to Neutral with a price target of $2.00, implying a downside of 31.5% from the Oct 1 close of $2.92.